Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 May;31(3):560-9.
doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy

Chi Hoon Maeng  1   2 , Sung Woo Ahn  3 , Seong-Yoon Ryu  3 , Sungjun Han  3 , Young Hyeh Ko  4 , Jun Ho Ji  5 , Won Seog Kim  2 , Seok Jin Kim  2
Affiliations
Comparative Study

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy

Chi Hoon Maeng et al. Korean J Intern Med. 2016 May.

Abstract

Background/aims: The Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 are well-known prognostic models for patients with follicular lymphoma (FL). However, their prognostic relevance has not been examined before in Korean patients with FL.

Methods: We reviewed clinical and laboratory information from our database of patients between 1995 and 2012. In total, 125 patients were stratified in three categories according to FLIPI or FLIPI2 scores: low-, intermediate-, and high-risk groups. We compared FLIPI and FLIPI2 in terms of progression-free survival (PFS) and overall survival (OS).

Results: Among the 125 patients, the prognostic value of FLIPI and FLIPI2 was evaluated in 73 patients who fulfilled the criteria of both prognostic models. Risk stratification by FLIPI and FLIPI2 showed significant differences in unfavorable parameters among each risk group, particularly between low- and intermediate-risk groups. The high-risk group b was significantly associated with poor PFS on both FLIPI and FLIPI2 (p < 0.05). However, the OS was significantly different only in the risk groups determined by FLIPI2 (p = 0.042). In a subgroup analysis of patients who received rituximab-containing chemotherapy, the risk stratification of both prognostic models showed a significant impact on PFS, especially in the low-risk group.

Conclusions: FLIPI and FLIPI2 are appropriate prognostic models in Korean FL patients, especially for discriminating low-risk patients from intermediate- and high-risk groups.

Keywords: Follicular lymphoma; Index; Prognosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials diagram of cohort. FLIPI, Follicular Lymphoma International Prognostic Index.
Figure 2.
Figure 2.
Progression-free survival and overall survival of (A, B) the entire follicular lymphoma cohort and (C, D) chemotherapy-treated patients (rituximab).
Figure 3.
Figure 3.
(A, B) Progression-free survival and (C, D) overall survival among subset populations based on FLIPI and FLIPI2 risk groups. FLIPI, Follicular Lymphoma International Prognostic Index.
Figure 4.
Figure 4.
(A, B) Progression-free survival and (C, D) overall survival among patients treated by rituximab-containing chemotherapy based on FLIPI and FLIPI2 risk groups. FLIPI, Follicular Lymphoma International Prognostic Index.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276. - PMC - PubMed
    1. Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol. 2012;47:92–104. - PMC - PubMed
    1. Park HJ, Park EH, Jung KW, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol. 2012;47:28–38. - PMC - PubMed
    1. Tan D, Horning SJ. Follicular lymphoma: clinical features and treatment. Hematol Oncol Clin North Am. 2008;22:863–882. - PubMed
    1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994. - PubMed

Publication types

MeSH terms

LinkOut - more resources